{"filing":{"accession_number":"0001193125-26-290823","cik":"0001811063","ticker":"NUVB","company_name":"Nuvation Bio Inc.","form":"8-K","filing_date":"2026-06-30","report_date":null,"primary_document":"d81296d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1811063/000119312526290823/d81296d8k.htm"},"events":[{"id":15072,"run_id":13444,"accession_number":"0001193125-26-290823","anchor_item_number":"2.03","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.97,"summary":"Nuvation Bio completed a $250 million registered public offering of 0.75% Convertible Senior Notes due 2032 on June 30, 2026, with an additional $37.5 million over-allotment option. The company used net proceeds of approximately $241.2 million to repay its senior secured loan agreement and for general corporate purposes, effectively refinancing its prior debt facility.","company_name":"Nuvation Bio Inc.","ticker":"NUVB","filing_date":"2026-06-30","form":"8-K","submitted_at":null,"items":[{"id":12702,"accession_number":"0001193125-26-290823","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Nuvation Bio completed a $250 million registered public offering of 0.75% Convertible Senior Notes due 2032 on June 30, 2026, pursuant to an Underwriting Agreement with Jefferies, Citigroup, and Cantor Fitzgerald. The filing discloses the Base Indenture and Supplemental Indenture governing the Notes, conversion terms, redemption provisions, and events of default. This is a material creation of a direct financial obligation—a debt issuance—distinct from equity dilution or covenant issues.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-01T02:24:01.668227+00:00","company_name":"","ticker":null,"filing_date":""},{"id":12703,"accession_number":"0001193125-26-290823","item_number":"1.02","item_title":"Termination of a Material Definitive Agreement.","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"Item 1.02 discloses termination of a material loan agreement through voluntary prepayment of approximately $58.5 million in aggregate obligations. While the Item nominally addresses termination, the operative event is the issuance of $250 million convertible senior notes (disclosed in Item 1.01 and the press releases) used to refinance and retire the prior debt facility. The primary material event is the creation of a new direct financial obligation (the convertible notes), making debt_issuance the most appropriate classification, though the termination of the prior loan agreement is also significant.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-01T02:24:01.668227+00:00","company_name":"","ticker":null,"filing_date":""},{"id":12704,"accession_number":"0001193125-26-290823","item_number":"2.03","item_title":"Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Nuvation Bio announced and priced an underwritten offering of $250.0 million aggregate principal amount of 0.75% Convertible Senior Notes due 2032, with an additional $37.5 million over-allotment option. The company intends to use net proceeds to repay its senior secured loan agreement and for general corporate purposes. This is a clear creation of a direct financial obligation under Item 2.03, constituting a material debt issuance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-01T02:24:01.668227+00:00","company_name":"","ticker":null,"filing_date":""},{"id":12705,"accession_number":"0001193125-26-290823","item_number":"8.01","item_title":"Other Events.","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Nuvation Bio entered into an Underwriting Agreement on June 25, 2026 to issue $250.0 million aggregate principal amount of 0.75% Convertible Senior Notes due 2032, with an additional $37.5 million over-allotment option. The company expects net proceeds of approximately $241.2 million to repay senior secured loan obligations and fund general corporate purposes. This is a material creation of a new direct financial obligation through debt issuance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-01T02:24:01.668227+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":12702,"accession_number":"0001193125-26-290823","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Nuvation Bio completed a $250 million registered public offering of 0.75% Convertible Senior Notes due 2032 on June 30, 2026, pursuant to an Underwriting Agreement with Jefferies, Citigroup, and Cantor Fitzgerald. The filing discloses the Base Indenture and Supplemental Indenture governing the Notes, conversion terms, redemption provisions, and events of default. This is a material creation of a direct financial obligation—a debt issuance—distinct from equity dilution or covenant issues.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-01T02:24:01.668227+00:00","company_name":"Nuvation Bio Inc.","ticker":"NUVB","filing_date":"2026-06-30"},{"id":12703,"accession_number":"0001193125-26-290823","item_number":"1.02","item_title":"Termination of a Material Definitive Agreement.","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"Item 1.02 discloses termination of a material loan agreement through voluntary prepayment of approximately $58.5 million in aggregate obligations. While the Item nominally addresses termination, the operative event is the issuance of $250 million convertible senior notes (disclosed in Item 1.01 and the press releases) used to refinance and retire the prior debt facility. The primary material event is the creation of a new direct financial obligation (the convertible notes), making debt_issuance the most appropriate classification, though the termination of the prior loan agreement is also significant.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-01T02:24:01.668227+00:00","company_name":"Nuvation Bio Inc.","ticker":"NUVB","filing_date":"2026-06-30"},{"id":12704,"accession_number":"0001193125-26-290823","item_number":"2.03","item_title":"Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Nuvation Bio announced and priced an underwritten offering of $250.0 million aggregate principal amount of 0.75% Convertible Senior Notes due 2032, with an additional $37.5 million over-allotment option. The company intends to use net proceeds to repay its senior secured loan agreement and for general corporate purposes. This is a clear creation of a direct financial obligation under Item 2.03, constituting a material debt issuance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-01T02:24:01.668227+00:00","company_name":"Nuvation Bio Inc.","ticker":"NUVB","filing_date":"2026-06-30"},{"id":12705,"accession_number":"0001193125-26-290823","item_number":"8.01","item_title":"Other Events.","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Nuvation Bio entered into an Underwriting Agreement on June 25, 2026 to issue $250.0 million aggregate principal amount of 0.75% Convertible Senior Notes due 2032, with an additional $37.5 million over-allotment option. The company expects net proceeds of approximately $241.2 million to repay senior secured loan obligations and fund general corporate purposes. This is a material creation of a new direct financial obligation through debt issuance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-01T02:24:01.668227+00:00","company_name":"Nuvation Bio Inc.","ticker":"NUVB","filing_date":"2026-06-30"}]}